145 related articles for article (PubMed ID: 33821389)
21. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
22. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
23. The role of
Lococo F; Rapicetta C; Filice A; Mengoli MC; Ricchetti T; Borrelli R; Paci M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):257-258. PubMed ID: 29636234
[No Abstract] [Full Text] [Related]
24. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
26. Massive pulmonary carcinoid tumor deemed inoperable until (68)Ga DOTATATE positron emission tomography/magnetic resonance imaging.
Ordidge KL; Brown JM; Succony L; Navani N; Hardavella G; Lawrence DR; Fraioli F; Groves A; Janes SM
Am J Respir Crit Care Med; 2014 Sep; 190(5):e16-7. PubMed ID: 25171317
[No Abstract] [Full Text] [Related]
27. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
Schraml C; Schwenzer NF; Sperling O; Aschoff P; Lichy MP; Müller M; Brendle C; Werner MK; Claussen CD; Pfannenberg C
Cancer Imaging; 2013 Mar; 13(1):63-72. PubMed ID: 23466785
[TBL] [Abstract][Full Text] [Related]
28. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
29. Synchronous bilateral bronchial carcinoid diagnosed with combined dual tracer ((18)F-FDG and (68)Ga-DOTATOC) PET/CT scans.
Paci M; Lococo F; Rapicetta C; Roncali M; Cavazza A; Treglia G; Sgarbi G
Rev Esp Med Nucl Imagen Mol; 2014; 33(4):247-8. PubMed ID: 24140023
[No Abstract] [Full Text] [Related]
30. Localization of Unknown Primary Site with
Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
[TBL] [Abstract][Full Text] [Related]
31. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
32. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
Mayerhoefer ME; Schuetz M; Magnaldi S; Weber M; Trattnig S; Karanikas G
Eur Radiol; 2012 Apr; 22(4):938-46. PubMed ID: 22080251
[TBL] [Abstract][Full Text] [Related]
33. A case of positive
Zilli A; Fanetti I; Conte D; Massironi S
Clin Imaging; 2018; 49():156-158. PubMed ID: 29529451
[TBL] [Abstract][Full Text] [Related]
34. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies.
Lincke T; Singer J; Kluge R; Sabri O; Paschke R
Thyroid; 2009 Apr; 19(4):381-9. PubMed ID: 19355828
[TBL] [Abstract][Full Text] [Related]
35. Enchondroma of Tibia as Potential False-positive Finding on 68Ga-DOTATOC PET/CT Scan.
Mahajan S; Bodei L; Huicochea Castellanos S; Grewal RK
Clin Nucl Med; 2019 Jan; 44(1):e57-e59. PubMed ID: 30371598
[TBL] [Abstract][Full Text] [Related]
36. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
[TBL] [Abstract][Full Text] [Related]
37. Role of 68Ga-DOTATOC PET/CT in carcinoids.
Jindal T; Kumar A; Kumar R; Dutta R
Pathol Int; 2010 Feb; 60(2):143-4. PubMed ID: 20398201
[No Abstract] [Full Text] [Related]
38. Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation.
von Falck C; Boerner AR; Galanski M; Knapp WH
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):812. PubMed ID: 17242919
[No Abstract] [Full Text] [Related]
39. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
[TBL] [Abstract][Full Text] [Related]
40. 68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation.
Chen S; Cheung SK; Wong KN; Wong KK; Ho CL
Clin Nucl Med; 2016 Dec; 41(12):959-960. PubMed ID: 27764046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
